GlassScriptPhysician profile
Alyssa L Marsillo
NPI 1568802692
$4,276.88
in general payments reported to CMS, 2019-2025
24 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $2,041 · 2023: $1,121 · 2024: $41.08 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.94 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,262.51 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $998.20 | 2021-2023 | Trulance, Xifaxan, Relistor |
| Abbvie INC. | $598.23 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.26 | 2021-2023 | Entyvio |
| Celgene Corporation | $222.84 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $131.26 | 2021-2023 | Sucraid |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $100.03 | 2021-2023 | Linzess |
| Pfizer INC. | $79.54 | 2021-2022 | |
| Ardelyx, INC. | $68.70 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $61.62 | 2021-2022 | |
| Genzyme Corporation | $49.28 | 2022-2023 | |
| Daiichi Sankyo INC. | $48.54 | 2021-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $48.13 | 2022-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $37.09 | 2022-2023 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $32.82 | 2022-2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $28.26 | 2021 | |
| Zimvie INC. | $27.13 | 2022 | |
| Medtronic, INC. | $23.56 | 2024 | Venaseal |
| Redhill Biopharma INC. | $22.26 | 2021 | |
| Amgen INC. | $21.77 | 2023 | Amjevita, Avsola |
| Orexo US, INC. | $17.52 | 2024 | Zubsolv |
| Novo Nordisk INC | $15.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Marsillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.